Faculty | Professors

Clinical & Research Interests

David P. Richman’s professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor, diseases of neuromuscular transmission, and pathogenesis and control of autoimmune response in myasthenia gravis. Richman has co-authored an extensive list of publications and book chapters on neurological disease and related topics. His research activities have focused on myasthenia, myasthenia gravis and multiple sclerosis.

Education

Johns Hopkins University School of Medicine
Baltimore, Maryland
M.D. 1969

Princeton University
Princeton, New Jersey
A.B. 1965

Internship

Albert Einstein College of Medicine
New York City, New York
1969-70
Medicine

Residency

Massachusetts General Hospital
Boston, Massachusetts
1973-74
Neurology

Albert Einstein College of Medicine
New York City, New York
1970-71
Neurology

Fellowships

Massachusetts General Hospital
Boston, Massachusetts
1974-76
Neurology

Harvard Medical School
Boston, Massachusetts
1974-75
Neurology

Board Certifications

American Board of Psychiatry and Neurology, 1976

Professional Memberships

American Academy of Family Physicians
American Academy of Neurology
American Association for the Advancement of Science
American Association of Immunologists
American Neurological Association
National Myasthenia Gravis Foundation, Inc.

Select Recent Publications

Agius, M.A., Richman, D.P., and Vincent, A. Specific antibodies in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related diseases. In Myasthenia Gravis and Related Disorders. H.J. Kaminski (Ed.). Humana Press: Totowa, New Jersey, pp.177-196, 2002.

Maselli, R.A., Kong, D., Bowe, C., McDonald, C., Ellis, W., Agius, M.A., Gomez, C.M., Richman, D.P., and Wollmann, R.L. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology 57: 279-289, 2001.

Richman, D.P. Thymectomy in myasthenia gravis: Problems and questions remain. Editorial. Journal Watch Neurology 3: 4, 2001.

Roberts, P.F., Venuta, F., Rendina, E., De Giancomo, T., Coloni, G.F., Follette, D.M., Richman, D.P. and Benfield, J.R. Thymectomy in the treatment of ocular myasthenia gravis. J. Thor. Cardiovasc. Surg. 122: 562-8, 2001.

Fairclough, R.H., Twaddle, G.M., Gudipati, E., Richman, D.P., Burkwall, D.A., and Josephs R. Mapping the mAb 383C epitope to a2(187-199) of the Torpedo acetylcholine receptor on the three dimensional model. J. Mol. Biol. 282:301-315, 1998.

Fairclough, R.H., Twaddle, G.M., Gudipati, E., Lin, M.Y. and Richman, D.P. Differential surface accessibility of a(187-199) in the Torpedo acetylcholine receptor a subunits. J. Mol. Biol. 282:317-330, 1998.

Lin MY, Twaddle GM, Gudipati E, Richman DP, Fairclough RH. mAb 383C binds to the (-subunit of the AChR associated with the high affinity tubocurarine site. Annals of New York Academy of Science 1998;841: 101-103

Fairclough RH, Gupidati E, Lin MY, Twaddle GM, Richman DP,Burkwall DA, Josephs R. A role for ((187-199)) in the conversion of agonist binding energy to the opening of the AChR receptor ion channel. Annals of New York Academy of Science 1998;841: 87-93

Kirvan CA, Zhu S, Richman DP, Agius MA. Expression and initial characterization of recombinant/hybrid anti-acetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. Annals of New York Academy of Science 1998;841: 466-468

Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, DuPont BL, Maselli RA. Antibody effector mechanisms in myasthenia gravis: the complement hypothesis Annals of New York Academy of Science 1998;841: 450-465